On Demand Webinar
Identifying Preclinical Immunotherapy Candidates Using a NHP Exploratory Toxicology Platform
Presenter: Dr Thomas Scullion
Immunotherapies can have unpredictable clinical toxicities, not observed in rodent preclinical studies. Instead, employing highly translatable exploratory NHP toxicology studies can de-risk clinical trials by assessing potential immune-related toxicities early in in vivo programs.
In this webinar, Dr Thomas Scullion discusses how to leverage NHP exploratory toxicology studies to guide and explore lead optimization, dosing paradigms, and future GLP studies. The enhanced translatability of NHP models is also highlighted, and their unique relevance for identifying immunotoxicities.
Watch this Webinar to Learn How:
- To design and implement flexible non-GLP NHP exploratory toxicology studies to answer multiple developmental questions, including dosing regimen and immunogenicity endpoints
- To incorporate in vitro assays using NHP and clinical samples to evaluate immune marker expression prior to starting a study
- NHPs provide a more translational preclinical model for elucidating immune-related toxicity
- To leverage exploratory NHP toxicology studies to assess immunotherapy safety, and de-risk future clinical trials
Who Should Watch:
- Decision makers who want to learn how to exploit the advantages of early immuno-safety screens in NHPs in order to de-risk clinical trials
- Researchers concerned about cytokine release syndrome and how to identify it in early-stage preclinical development
- Scientists developing immunotherapies who want to learn more about maximizing preclinical immuno-safety data
About The Presenter:
Thomas Scullion, PhD - Senior Director of Business Development at CrownBio has extensive experience guiding clients’ early drug discovery work through to clinical trials. At CrownBio, he specializes in pharmacology, toxicology, and bioanalytics using translational animal models. Thomas holds a PhD in Neuropharmacology, and previously worked at Symbiosis Pharmaceutical Services Limited and Charles River Laboratories.